Palbociclib Shows Benefit in HR+ HER2+ Metastatic Breast Cancer – the PATINA Trial - report from SABCS2024

from Medical Digest & Congress Report · host Medical Congress News

Otto Metzger, MD presented late-breaking results of the phase 3 PATINA trial showing addition of CDK4/6 inhibitor palbociclib to standard therapy led to a 15-month improvement in PFS in HR+, HER2+ metastatic breast cancer at San Antonio Breast Cancer Symposium 2024. Video: https://medicaldigest.org/scientific-contents/interview:palbociclib-shows-benefit-hr-her2-metastatic-breast-cancer-patina-trial

Episode metadata supplied by the publisher feed · Published Dec 20, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

Palbociclib Shows Benefit in HR+ HER2+ Metastatic Breast Cancer – the PATINA Trial - report from SABCS2024

0:00 4:38

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Medical Digest & Congress Report?

This episode is 4 minutes long.

When was this Medical Digest & Congress Report episode published?

This episode was published on December 20, 2024.

Can I download this Medical Digest & Congress Report episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!